220 related articles for article (PubMed ID: 29048629)
1. Inhibition of neuroblastoma proliferation by PF-3758309, a small-molecule inhibitor that targets p21-activated kinase 4.
Li Z; Li X; Xu L; Tao Y; Yang C; Chen X; Fang F; Wu Y; Ding X; Zhao H; Li M; Qian G; Xu Y; Ren J; Du W; Wang J; Lu J; Hu S; Pan J
Oncol Rep; 2017 Nov; 38(5):2705-2716. PubMed ID: 29048629
[TBL] [Abstract][Full Text] [Related]
2. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
3. Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer.
Zhao CC; Zhan MN; Liu WT; Jiao Y; Zhang YY; Lei Y; Zhang TT; Zhang CJ; Du YY; Gu KS; Wei W
Cancer Lett; 2020 Nov; 493():120-127. PubMed ID: 32829006
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth.
Murray BW; Guo C; Piraino J; Westwick JK; Zhang C; Lamerdin J; Dagostino E; Knighton D; Loi CM; Zager M; Kraynov E; Popoff I; Christensen JG; Martinez R; Kephart SE; Marakovits J; Karlicek S; Bergqvist S; Smeal T
Proc Natl Acad Sci U S A; 2010 May; 107(20):9446-51. PubMed ID: 20439741
[TBL] [Abstract][Full Text] [Related]
5. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
[TBL] [Abstract][Full Text] [Related]
6. The Cdc42 Effector Kinase PAK4 Localizes to Cell-Cell Junctions and Contributes to Establishing Cell Polarity.
Selamat W; Tay PL; Baskaran Y; Manser E
PLoS One; 2015; 10(6):e0129634. PubMed ID: 26068882
[TBL] [Abstract][Full Text] [Related]
7. p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT- and ERK-dependent activation of NF-κB pathway.
Tyagi N; Bhardwaj A; Singh AP; McClellan S; Carter JE; Singh S
Oncotarget; 2014 Sep; 5(18):8778-89. PubMed ID: 25238288
[TBL] [Abstract][Full Text] [Related]
8. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells.
Zhang J; Wang J; Guo Q; Wang Y; Zhou Y; Peng H; Cheng M; Zhao D; Li F
Cancer Lett; 2012 Apr; 317(1):24-32. PubMed ID: 22085492
[TBL] [Abstract][Full Text] [Related]
9. MiR-199a/b-3p suppresses migration and invasion of breast cancer cells by downregulating PAK4/MEK/ERK signaling pathway.
Li SQ; Wang ZH; Mi XG; Liu L; Tan Y
IUBMB Life; 2015 Oct; 67(10):768-77. PubMed ID: 26399456
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of 1-phenanthryl-tetrahydroisoquinoline derivatives as novel p21-activated kinase 4 (PAK4) inhibitors.
Song S; Li X; Guo J; Hao C; Feng Y; Guo B; Liu T; Zhang Q; Zhang Z; Li R; Wang J; Lin B; Li F; Zhao D; Cheng M
Org Biomol Chem; 2015 Mar; 13(12):3803-18. PubMed ID: 25705811
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of P21-activated kinase 4 is associated with poor prognosis in non-small cell lung cancer and promotes migration and invasion.
Cai S; Ye Z; Wang X; Pan Y; Weng Y; Lao S; Wei H; Li L
J Exp Clin Cancer Res; 2015 May; 34(1):48. PubMed ID: 25975262
[TBL] [Abstract][Full Text] [Related]
12. p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma.
Qasim SL; Sierra L; Shuck R; Kurenbekova L; Patel TD; Rajapakshe K; Wulff J; Nakahata K; Kim HR; Landesman Y; Unger TJ; Coarfa C; Yustein JT
Oncogene; 2021 Feb; 40(6):1176-1190. PubMed ID: 33414491
[TBL] [Abstract][Full Text] [Related]
13. (-)-β-hydrastine suppresses the proliferation and invasion of human lung adenocarcinoma cells by inhibiting PAK4 kinase activity.
Guo B; Li X; Song S; Chen M; Cheng M; Zhao D; Li F
Oncol Rep; 2016 Apr; 35(4):2246-56. PubMed ID: 26821251
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of p21-activated kinase 4 expression suppresses the proliferation of Hep-2 laryngeal carcinoma cells via activation of the ATM/Chk1/2/p53 pathway.
Sun X; Liu B; Wang J; Li J; Ji WY
Int J Oncol; 2013 Feb; 42(2):683-9. PubMed ID: 23229348
[TBL] [Abstract][Full Text] [Related]
15. Repositioning Potential of PAK4 to Osteoclastic Bone Resorption.
Choi SW; Yeon JT; Ryu BJ; Kim KJ; Moon SH; Lee H; Lee MS; Lee SY; Heo JC; Park SJ; Kim SH
J Bone Miner Res; 2015 Aug; 30(8):1494-507. PubMed ID: 25640698
[TBL] [Abstract][Full Text] [Related]
16. Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma.
Lu SX; Zhang CZ; Luo RZ; Wang CH; Liu LL; Fu J; Zhang L; Wang H; Xie D; Yun JP
Cancer Lett; 2017 Aug; 402():71-80. PubMed ID: 28577975
[TBL] [Abstract][Full Text] [Related]
17. P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer.
Li Y; Wang D; Zhang H; Wang C; Dai W; Cheng Z; Wang G; Li F
Anat Rec (Hoboken); 2013 Oct; 296(10):1561-7. PubMed ID: 23873832
[TBL] [Abstract][Full Text] [Related]
18. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
Fulciniti M; Martinez-Lopez J; Senapedis W; Oliva S; Lakshmi Bandi R; Amodio N; Xu Y; Szalat R; Gulla A; Samur MK; Roccaro A; Linares M; Cea M; Baloglu E; Argueta C; Landesman Y; Shacham S; Liu S; Schenone M; Wu SL; Karger B; Prabhala R; Anderson KC; Munshi NC
Blood; 2017 Apr; 129(16):2233-2245. PubMed ID: 28096095
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.
Tabusa H; Brooks T; Massey AJ
Mol Cancer Res; 2013 Feb; 11(2):109-21. PubMed ID: 23233484
[TBL] [Abstract][Full Text] [Related]
20. Overexpressed PAK4 promotes proliferation, migration and invasion of choriocarcinoma.
Zhang HJ; Siu MK; Yeung MC; Jiang LL; Mak VC; Ngan HY; Wong OG; Zhang HQ; Cheung AN
Carcinogenesis; 2011 May; 32(5):765-71. PubMed ID: 21325635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
